Results for tag: "Autologous Matrix Induced Chondrogenesis"

Autologous Matrix Induced Chondrogenesis (AMIC) is a medical procedure used in orthopedics that combines microfracture surgery with the application of a biodegradable matrix to treat cartilage defects. This technique is designed to stimulate the growth of new cartilage tissue and is typically used in the treatment of articular cartilage damage in the knee, hip, ankle, and shoulder. AMIC represents a specialized subset of the orthopedic devices market, which is broader and includes implants, prostheses, and other surgical tools used to treat musculoskeletal disorders. Orthopedic devices are essential for the stabilization and reconstruction of bones and joints following trauma or degenerative diseases. The market for these devices encompasses a diverse range of products tailored to various orthopedic conditions. Within this context, AMIC is categorized under the cartilage repair and regeneration segment, which focuses specifically on repairing damaged cartilage. The AMIC procedure is considered a minimally invasive treatment option that offers patients the potential for improved healing and recovery times compared to traditional open surgeries. Several companies have ventured into the AMIC market, each offering proprietary matrices and surgical kits to facilitate the procedure. Notable players in this space include Geistlich Pharma, Medtronic, Zimmer Biomet, Stryker, and Arthrex. These companies are involved in the research, development, production, and marketing of products related to Autologous Matrix Induced Chondrogenesis and are active in advancing the Show Less Read more